Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT05700370 Enrolling by invitation - Prostate Cancer Clinical Trials

MyProstateScore Equivalency With and Without DRE

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to quantify the concordance of MPS results between first-catch urine samples collected post-DRE and those collected without a DRE.

NCT ID: NCT05319145 Enrolling by invitation - Prostate Cancer Clinical Trials

PeRsonalizing the Approach to the Oncologic Frail Individual Through Tailored Assessment and Intervention (PROFIT Study)

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

The PROFIT study has two complementary aims. The first aim is to compare, in a cohort study enrolling N=257 older adults (>65 years) with lung, gastrointestinal and prostate cancer, different easy measures of frailty (Geriatric 8 questionnaire (G8), Short physical Performance Battery (SPPB) and the IF-VIG), testing their ability to predict survival, functional status (ECOG, Barthel Index), quality of life (EuroQol5D) and resources utilization (visits, hospital admissions, treatments) at 3, 6 and 12 months. The second aim, which motivates the registration in, is to conduct a randomized controlled trial (RCT) enrolling N=134 patients per group, with similar characteristics to those enrolled for aim 1, but with mild-moderate frailty (G8≤14 points); we will compare a multi-component CGA-based intervention including physical exercise and nutritional recommendations with usual care, measuring the impact on the same outcomes as for aim 1, at 3 and 6 months. The use of ad hoc eHealth solutions (App/platform for exercise) will foster patients' empowerment and sustainability of the intervention. We will also assess patients, caregivers, and professionals' experience with the intervention through focus groups. Participants will be recruited from outpatients and from post-acute care units.

NCT ID: NCT05223218 Enrolling by invitation - Breast Cancer Clinical Trials

Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study

Start date: August 25, 2021
Study type: Observational

This Pilot Study is to investigate the tear proteins in a multitude of cancer types and indulge in biomarker discovery to manufacture simple, accurate, and novel tear-based diagnostic tests.

NCT ID: NCT05160480 Enrolling by invitation - Breast Cancer Clinical Trials

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).

NCT ID: NCT05078359 Enrolling by invitation - Prostate Cancer Clinical Trials

Optimizing Positive Predicting Value of Prostate MRI

Start date: January 1, 2022
Study type: Observational

The PROMOD study is an international multicenter retrospective Project. The aim is to create a comprehensive database that will include multiple heterogeneous cohorts in order to explore inter-center differences in the accuracy of Magnetic Resonance Imaging (MRI) in the diagnosis of prostate cancer and to define optimal strategies for the selection of men at risk of clinically significant prostate cancer who might benefit from biopsies.

NCT ID: NCT04986280 Enrolling by invitation - Prostate Cancer Clinical Trials

Diagnostic Accuracy and Performance of 18F-PSMA-1007

Start date: July 13, 2021
Study type: Observational

Whereas 18F-PSMA-1007 has rapidly established itself as a radiotracer for the investigation of prostate cancer, there are no studies confirming its diagnostic performance. The purpose of this study is to determine the diagnostic performance for this radiotracer.

NCT ID: NCT04890314 Enrolling by invitation - Prostate Cancer Clinical Trials

Prostate Cancer - Comparative Outcomes of New Conceptual Paradigms for Treatment

Start date: May 15, 2021
Study type: Observational

This study will use a population-based cohort design to study men with newly diagnosed low- and intermediate-risk prostate cancer at high-volume centers in Southern California (SCa) and New York State (NYS). Complications of contemporary treatments for prostate cancer and quality of life outcomes, such as general health, urinary, sexual, and bowel function, cancer anxiety, and treatment regret will be compared and tracked over the course of this study.

NCT ID: NCT04746638 Enrolling by invitation - Prostate Cancer Clinical Trials

Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26

Start date: February 1, 2021
Phase: Phase 1
Study type: Interventional

The study should evaluate the biological distribution of 99mTc-RM26 in patients with prostate cancer and breast cancer. The primary objective are: 1. To assess the distribution of 99mTc- RM26 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of 99mTc- RM26. 3. To study the safety and tolerability of the drug 99mTc- RM26 after a single injection in a diagnostic dosage. The secondary objective are: 1. To compare the obtained 99mTc- RM26 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer and breast cancer patients.

NCT ID: NCT04465214 Enrolling by invitation - Prostate Cancer Clinical Trials

Mobile Sensor Technologies to Assess General Symptomology of People With Cancer

Start date: November 23, 2020
Study type: Observational

Background: Many digital devices, such as smartphones and activity monitors, have sensors to collect and track health data. Researchers believe these devices may be able to transform the quality of clinical research and healthcare. They believe they may be able to help assess the symptoms, response to therapy, and quality of life of people with cancer. Objective: To collect data from people with cancer using an Apple iPhone alone or together with an Apple Watch in order to assess their symptoms and activity levels. Eligibility: People ages 18 years and over who have cancer and receiving treatment for their cancer in another NIH protocol Design: Participants will be screened with their medical records. Participants will have a baseline visit. They will have visits every 2 4 weeks based on the treatment protocol in which they are co-enrolled. Then they will have a follow-up visit 4 months after the baseline visit. Visits include: Medical history Physical exam Karnofsky Performance Scale/Eastern Cooperative Oncology Group performance status to see how their disease affects daily activities The study team will use an iPhone to collect data. This includes a 6-minute walk test and tests of hearing, reaction time, and cognitive status. Questionnaires If participants have an iPhone, an Apple Watch will be provided to them after training at the baseline visit. Continuous measurement of their activity will be recorded by the watch between 2 visits. They will wear the watch while they are on study. They will wear the watch while it is not being charged. They should charge the watch at night time. They will have the watch for 4 months.

NCT ID: NCT04399876 Enrolling by invitation - Prostate Cancer Clinical Trials

Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

Start date: June 22, 2020
Phase: Phase 1
Study type: Interventional

In this research study, is assessing the feasibility of using an MR-guided implantable microdevice to measure tumor response to chemotherapy and other clinically relevant drugs in participants that have prostate cancer and are scheduled for a radical prostatectomy. The name of the study intervention involved in this study is: - Implantation of a MR-guided microdevice